



Stefan Aebi

Kontakt

Stefan Aebi

Publikationen (17)

Zander T, Pabst T, Schär S, Aebi S, Mey U, Novak U, Lerch E, Rhyner Agocs G, Goede J, Maniecka Z, Hayoz S, Rüfer A, Renner C, Driessen C. Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial. *Leukemia* 2023; 37:699-701.

Begré U, Jörgler M, Aebi S, Amstutz U, Largiadèr C. Clinical Implementation of Pharmacogenetic Testing to Prevent Early-Onset Fluoropyrimidine-Related Toxicity in Cancer Patients in Switzerland. *Front Pharmacol* 2022; 13:885259.

Hamzic S, Aebi S, Jörgler M, Montemurro M, Ansari M, Amstutz U, Largiadèr C. Fluoropyrimidine chemotherapy: recommendations for DPYD genotyping and therapeutic drug monitoring of the Swiss Group of Pharmacogenomics and Personalised Therapy. *Swiss Med Wkly* 2020; 150:w20375.

Hamzic S, Amstutz U, López-Fernández L, García-González X, Schellens J, Meulendijks D, Thomlinson I, Palles C, Aebi S, Jörgler M, Froehlich T, Kummer D, Largiadèr C. Evaluating the role of ENOSF1 and TYMS variants as predictors in fluoropyrimidine-related toxicities: An IPD meta-analysis. *Pharmacol Res* 2019; 152:104594.

Schmid S, Zaman K, Weder P, von Moos R, Thürlimann B, Rochlitz C, Pestalozzi B, Pagani O, Oehlschlegel C, Nolè F, Munzone E, Mamot C, Goldhirsch A, Aebi S, Klingbiel D, Ruhstaller T. Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data. *BMC cancer* 2019; 19:902.

Wapnir I, Gelber S, Coates A, Gelber R, Rastogi P, Regan M, Wolmark N, Aebi S, International Breast Cancer Study Group, NRG Oncology, GEICAM Spanish Breast Cancer Group, BOOG Dutch Breast Cancer Trialists' Group, Geyer C, Mamounas E, Thürlimann B, Price K, Anderson S, Robidoux A, Martín M, Nortier J, Paterson A, Rimawi M, Láng I, Baena-Cañada J, Breast International Group. Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial. *J Clin Oncol* 2018; 36:1073-1079.

Colleoni M, Di Lauro V, Gombos A, Ruhstaller T, Burstein H, Ribi K, Bernhard J, Viale G, Maibach R, Rabaglio-Poretti M, Gelber R, Coates A, Di Leo A, Regan M, Goldhirsch A, O'Reilly S, Müller B, Marth C, Luo W, Karlsson P, Chirgwin J, Aebi S, Jerusalem G, Neven P, Hitre E, Graas M, Simoncini E, Kamby C, Thompson A, Loibl S, Gavilá J, Kuroi K, SOLE Investigators. Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. *Lancet Oncol* 2017; 19:127-138.

Pestalozzi B, Novak U, Nussbaum C, Seifert B, Bigler M, Bize V, Vilei S, Rageth C, Aebi S, Borner M, Buser K, Tausch C, Dedes K, Rochlitz C, Zimmermann S, von Moos R, Winterhalder R, Ruhstaller T, Mueller A. Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10). *BMC cancer* 2017; 17:265.

Kummer D, Froehlich T, Joergler M, Aebi S, Sistonen J, Amstutz U, Largiadèr C. Dihydropyrimidinase and β -ureidopyropionase gene variation and severe fluoropyrimidine-related toxicity. *Pharmacogenomics* 2015; 16:1367-77.

Froehlich T, Amstutz U, Aebi S, Jörgler M, Largiadèr C. Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity. *Int J Cancer* 2014; 136:730-9.

Decensi A, Coates A, Goldhirsch A, Gelber R, Price K, Johansson H, Zaman K, Schönenberger A, Debled M, Campone M, Monnier A, Tondini C, McIntosh C, Thürlimann B, Guerrieri-Gonzaga A, Sun Z, Aebi S. Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences. *Breast Cancer Res Treat* 2014; 144:321-9.

Aebi S, Mamounas E, Geyer C, Price K, Coates A, Gelber R, Rastogi P, Wolmark N, Wapnir I, Murray E, Thürlimann B, Cañada J, Gelber S, Anderson S, Láng I, Robidoux A, Martín M, Nortier J, Paterson A, Rimawi M, CALOR investigators. Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial. *Lancet Oncol* 2014; 15:156-63.

Zaman K, Thürlimann B, Aebi S. Optimal sequence of tamoxifen and aromatase inhibitors to prevent bone loss. *J Clin Oncol* 2013; 31:3440-1.

Huober J, Widmer I, von Rohr L, Müller A, von Moos R, Güth U, Aebi S, Rochlitz C, Baumann M, Thürlimann B. Trastuzumab Treatment beyond Progression in Advanced Breast Cancer: Patterns of Care in Six Swiss Breast Cancer Centers. *Oncology* 2011; 81:160-166.

Antonov J, Aebi S, Altermatt H, Viale G, Giobbie-Hurder A, Thürlimann B, Oberli A, Baltzer A, Wirapati P, Delorenzi M, Popovici V, Jaggi R. Molecular risk assessment of BIG 1-98 participants by expression profiling using RNA from archival tissue. *BMC cancer* 2010; 10:37.

Bernhard J, Coates A, Goldhirsch A, Price K, Thürlimann B, Aebi S, Collins J, Murray E, Forbes J, Gelber R, Hüryny C, Castiglione-Gertsch M, Zahrieh D, International Breast Cancer Study Group Trial VIII. Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII. *JCO* 2007; 25:263-70.

Thürlimann B, Rochlitz C, Aebi S, Perey L, Pagani O, Ballabeni P, Senn I, Köberle D, Hess D, Goldhirsch A. Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial. *Breast Cancer Res Treat* 2004; 85:247-54.

Projekte (0)

Keine Resultate gefunden.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch